{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:49:10Z","timestamp":1785919750085,"version":"3.56.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.radonc.2026.111412","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:41:59Z","timestamp":1770828119000},"page":"111412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Optimizing prostate cancer stereotactic body radiotherapy: margins, dose, or target volume-de-intensification?"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-4873","authenticated-orcid":false,"given":"Jennifer","family":"Le Guevelou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9883","authenticated-orcid":false,"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111412_b0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-025-01071-7","article-title":"Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: clinical evidence and emerging mitigation strategies","author":"Le Guevelou","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.radonc.2026.111412_b0010","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111412_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2026.111363","article-title":"Acute adverse events in the DESTINATION 1 trial: a prospective prostate SBRT dose de-escalation feasibility study","volume":"216","author":"Cooper","year":"2026","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2026.111412_b0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","article-title":"Radiation dose to the intraprostatic urethra correlates strongly with urinary toxicity after prostate stereotactic body radiation therapy: a combined analysis of 23 prospective clinical trials","volume":"112","author":"Leeman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111412_b0025","first-page":"00397","article-title":"Exploring factors associated with late urinary toxicity after prostate stereotactic body radiotherapy: findings from the PACE-B study","volume":"S0302\u20132838","author":"Ratnakumaran","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111412_b0030","article-title":"Urethra-sparing prostate cancer radiotherapy: current practices and future insights from an international survey","volume":"51","author":"Gu\u00e9velou","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111412_b0035","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2023.10.015","volume":"118","author":"Neilsen","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111412_b0040","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.clon.2018.05.001","article-title":"An investigation of dosimetric correlates of acute toxicity in prostate stereotactic body radiotherapy: dose to urinary trigone is associated with acute urinary toxicity","volume":"30","author":"Henderson","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111412_b0045","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging\u2013guided vs computed tomography\u2013guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111412_b0050","article-title":"Focal radiation therapies for localized prostate cancer: a systematic review of clinical evidence and outcomes","author":"Le Gu\u00e9velou","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.radonc.2026.111412_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1143716","article-title":"Stereotactic focal radiotherapy as an alternative treatment for low-risk prostate cancer: results of a single-arm monocenter phase-II trial","volume":"13","author":"Nguyen","year":"2023","journal-title":"Front Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026000502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026000502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:16:34Z","timestamp":1785917794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026000502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":11,"alternative-id":["S0167814026000502"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111412","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing prostate cancer stereotactic body radiotherapy: margins, dose, or target volume-de-intensification?","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111412","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111363","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111412"}}